Date:11/12/2009

CAL PARTNERS, INC. (a development stage company) CONDENSED BALANCE SHEETS September 30, December 31, 2009 2008 ------------- ------------ (unaudited) ASSETS Current Assets: Cash and cash equivalents $4,912,346 $11,766,629 Interest receivable - 12,153 Prepaid expenses 81,770 136,374 ------ ------- Total current assets 4,994,116 11,915,156 Property and equipment, net 73,231 96,376 Deposits 10,511 21,436 ------ ------ Total assets $5,077,858 $12,032,968 ========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $163,067 $332,707 Accrued expenses and other liabilities 102,627 1,097,410 ------- --------- Total current liabilities 265,694 1,430,117 Accrued expenses and other liabilities, non-current 49,596 42,636 ------ ------ Total liabilities 315,290 1,472,753 Total stockholders' equity
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
4. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
7. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering